New preclinical findings suggest chemotherapy can enhance therapeutic cancer vaccination, with viral-vector vaccine platforms benefiting when combined with specific regimens. The work evaluated viral-vector therapeutic vaccines in mice alongside carboplatin plus paclitaxel (CarboTaxol) and found the combined approach outperformed the vaccine alone. The investigators explored mechanisms that had previously been associated with chemotherapy benefits, including myeloid cell depletion, while also identifying additional contributors. They reported that the adjuvant activity depended on the transcription factor TCF-1, with improvements disappearing in TCF-1 knockout animals. In the study, cyclophosphamide also produced adjuvant effects, while gemcitabine did not, implying the potentiation is chemotherapy-type specific. The results also extended to combination strategies including a triple regimen—therapeutic vaccine plus CarboTaxol plus anti–PD-1—showing superior effectiveness compared with other combinations. The authors noted that clinical translation will require attention to the order and timing of administrations, given the known importance of sequencing when integrating chemotherapy and immune-based approaches.